Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Gene Therapy00:59

Gene Therapy

28.2K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
28.2K
Gene Therapy00:59

Gene Therapy

4.8K
4.8K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.4K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.4K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

91
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91
What is Genetic Engineering?00:49

What is Genetic Engineering?

81.7K
Overview
81.7K
CRISPR01:59

CRISPR

60.1K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
60.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rational engineering of the P5 TRS-mimic site and REP78/68 start codon yields promoter variants that improve rAAV purity while maintaining high titers.

Molecular therapy. Advances·2026
Same author

Outcomes and Surgical Management of Malignant Rhabdoid Tumor of the Kidney: A Report From the Pediatric Surgical Oncology Research Collaborative.

Pediatric blood & cancer·2026
Same author

International Society of Paediatric Surgical Oncology (IPSO) Minimally Invasive Surgery (MIS) Guidelines.

Ecancermedicalscience·2026
Same author

Symptomatic Recurrent Splenomegaly Following Partial Splenectomy in Patients With Hereditary Spherocytosis.

Pediatric blood & cancer·2026
Same author

Developmental reprogramming underlies chemotherapy resistance in favorable-histology Wilms tumor.

Cell reports·2026
Same author

Capturing clinically actionable copy number alterations in Wilms tumor using nanopore sequencing.

Research square·2026

Related Experiment Video

Updated: Apr 11, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K

Haemophilia gene therapy: Progress and challenges.

Elsa Lheriteau1, Andrew M Davidoff2, Amit C Nathwani3

  • 1Katharine Dormandy Haemophilia Centre and Thrombosis Unit, Royal Free NHS Foundation Trust, UK; Department of Haematology, UCL Cancer Institute, UK.

Blood Reviews
|June 8, 2015
PubMed
Summary

Gene therapy offers a potential cure for haemophilia B by enabling continuous production of factor IX (FIX) protein. A recent study demonstrated long-term therapeutic FIX levels after a single adeno-associated virus vector infusion.

Keywords:
Factor IXFactor VIIIGene therapyHaemophiliaVectors

More Related Videos

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

8.2K
Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications
03:52

Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications

Published on: February 9, 2024

4.3K

Related Experiment Videos

Last Updated: Apr 11, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.9K
Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells
11:16

Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells

Published on: February 15, 2019

8.2K
Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications
03:52

Author Spotlight: Efficient Adeno-Associated Virus Isolation for Pre-Clinical Applications

Published on: February 9, 2024

4.3K

Area of Science:

  • * Hematology
  • * Gene Therapy
  • * Virology

Background:

  • * Current haemophilia treatment involves lifelong, expensive clotting factor infusions, which are not curative.
  • * Gene therapy presents a potential curative approach for haemophilia by enabling endogenous protein expression.
  • * Severe haemophilia B requires continuous management of bleeding risks.

Purpose of the Study:

  • * To establish proof-of-concept for gene therapy as a curative treatment for severe haemophilia B.
  • * To evaluate the long-term efficacy and safety of adeno-associated virus (AAV)-mediated factor IX (FIX) gene transfer.
  • * To assess the potential of gene therapy to alter the treatment paradigm for haemophilia.

Main Methods:

  • * Single intravenous administration of an adeno-associated virus vector encoding an optimized FIX gene in patients with severe haemophilia B.
  • * Long-term monitoring of plasma FIX levels and assessment for persistent or late toxicity.
  • * Dose-dependent analysis of FIX expression and therapeutic efficacy.

Main Results:

  • * Achieved a long-term (over 4 years) dose-dependent increase in plasma FIX levels.
  • * Maintained FIX levels within the therapeutic range.
  • * Demonstrated no persistent or late toxicity associated with the gene therapy vector.

Conclusions:

  • * Gene therapy using AAV vectors is a viable proof-of-concept for treating severe haemophilia B.
  • * This approach has the potential to offer a curative solution, moving beyond traditional factor replacement therapy.
  • * Further research is needed to overcome remaining hurdles for widespread clinical application.